Sci Rep:不同格林森评分前列腺癌中类固醇激素受体和基质细胞标记表达比较

2018-10-11 AlexYang MedSci原创

抗血管生成和免疫调节药物最近的发展表明了肿瘤微环境(TME)在癌症研究中越来越重要。最近,有研究人员通过比较不同GS组中类固醇激素受体的组织表达情况、癌症激活成纤维细胞(CAF)标记和血管密度情况,调查了格林森评分(GS)与TME之间的相关性。匹配的患者群体组成了不同的GS分组(6-7-8)。研究人员利用6个样本/患者的组织芯片进行免疫组化染色。研究人员对染色的片子进行数字化,并对基质和上皮进行选

血管生成和免疫调节药物最近的发展表明了肿瘤微环境(TME)在癌症研究中越来越重要。

最近,有研究人员通过比较不同GS组中类固醇激素受体的组织表达情况、癌症激活成纤维细胞(CAF)标记和血管密度情况,调查了格林森评分(GS)与TME之间的相关性。匹配的患者群体组成了不同的GS分组(6-7-8)。研究人员利用6个样本/患者的组织芯片进行免疫组化染色。研究人员对染色的片子进行数字化,并对基质和上皮进行选择性的标注,还对所有选择的区域标记的表达进行定量的分析。研究发现,与低GS前列腺癌和配对的前列腺癌非肿瘤组织相比,一些激素诱导的受体的表达在基质中减少,CAF表型和血管密度在高GS前列腺癌中均增加。

最后,研究人员指出,他们的研究阐释了前列腺癌分化和TME组分之间的复杂联系,表明了不同的GS与TME中不同的作用靶标相关。标准化的数字成像分析工具的使用产生了大量的可重复的定量数据,与经典的半定量和依赖观察的免疫组化相比,是一种新的和有效信息更多的技术。

原始出处:

Thomas Gevaert, Yves-Rémi Van Eycke, Thomas Vanden Broeck et al. Comparing the expression profiles of steroid hormone receptors and stromal cell markers in prostate cancer at different Gleason scores. Sci Rep. 25 Sep 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1757127, encodeId=4fa11e571278f, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Wed Dec 12 22:49:00 CST 2018, time=2018-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664262, encodeId=b4ae1664262e4, content=<a href='/topic/show?id=23416231447' target=_blank style='color:#2F92EE;'>#格林森评分#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62314, encryptionId=23416231447, topicName=格林森评分)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ecb25719968, createdName=ms5353107019656438, createdTime=Sat Mar 16 16:49:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954582, encodeId=3d31195458243, content=<a href='/topic/show?id=cb1de613583' target=_blank style='color:#2F92EE;'>#类固醇激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76135, encryptionId=cb1de613583, topicName=类固醇激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Mar 31 04:49:00 CST 2019, time=2019-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313408, encodeId=8eab131340818, content=<a href='/topic/show?id=d59be61251d' target=_blank style='color:#2F92EE;'>#类固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76125, encryptionId=d59be61251d, topicName=类固醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sat Oct 13 03:49:00 CST 2018, time=2018-10-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1757127, encodeId=4fa11e571278f, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Wed Dec 12 22:49:00 CST 2018, time=2018-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664262, encodeId=b4ae1664262e4, content=<a href='/topic/show?id=23416231447' target=_blank style='color:#2F92EE;'>#格林森评分#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62314, encryptionId=23416231447, topicName=格林森评分)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ecb25719968, createdName=ms5353107019656438, createdTime=Sat Mar 16 16:49:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954582, encodeId=3d31195458243, content=<a href='/topic/show?id=cb1de613583' target=_blank style='color:#2F92EE;'>#类固醇激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76135, encryptionId=cb1de613583, topicName=类固醇激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Mar 31 04:49:00 CST 2019, time=2019-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313408, encodeId=8eab131340818, content=<a href='/topic/show?id=d59be61251d' target=_blank style='color:#2F92EE;'>#类固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76125, encryptionId=d59be61251d, topicName=类固醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sat Oct 13 03:49:00 CST 2018, time=2018-10-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1757127, encodeId=4fa11e571278f, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Wed Dec 12 22:49:00 CST 2018, time=2018-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664262, encodeId=b4ae1664262e4, content=<a href='/topic/show?id=23416231447' target=_blank style='color:#2F92EE;'>#格林森评分#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62314, encryptionId=23416231447, topicName=格林森评分)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ecb25719968, createdName=ms5353107019656438, createdTime=Sat Mar 16 16:49:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954582, encodeId=3d31195458243, content=<a href='/topic/show?id=cb1de613583' target=_blank style='color:#2F92EE;'>#类固醇激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76135, encryptionId=cb1de613583, topicName=类固醇激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Mar 31 04:49:00 CST 2019, time=2019-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313408, encodeId=8eab131340818, content=<a href='/topic/show?id=d59be61251d' target=_blank style='color:#2F92EE;'>#类固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76125, encryptionId=d59be61251d, topicName=类固醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sat Oct 13 03:49:00 CST 2018, time=2018-10-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1757127, encodeId=4fa11e571278f, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Wed Dec 12 22:49:00 CST 2018, time=2018-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664262, encodeId=b4ae1664262e4, content=<a href='/topic/show?id=23416231447' target=_blank style='color:#2F92EE;'>#格林森评分#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62314, encryptionId=23416231447, topicName=格林森评分)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ecb25719968, createdName=ms5353107019656438, createdTime=Sat Mar 16 16:49:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954582, encodeId=3d31195458243, content=<a href='/topic/show?id=cb1de613583' target=_blank style='color:#2F92EE;'>#类固醇激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76135, encryptionId=cb1de613583, topicName=类固醇激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Mar 31 04:49:00 CST 2019, time=2019-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313408, encodeId=8eab131340818, content=<a href='/topic/show?id=d59be61251d' target=_blank style='color:#2F92EE;'>#类固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76125, encryptionId=d59be61251d, topicName=类固醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sat Oct 13 03:49:00 CST 2018, time=2018-10-13, status=1, ipAttribution=)]

相关资讯

Gastroenterology:实现治疗响应的溃疡性结肠炎患者可停止甲氨蝶呤持续治疗

研究认为,对于已经实现无类固醇治疗响应的溃疡性结肠炎患者,持续的甲氨蝶呤治疗意义不显著

Int Forum Allergy Rhinol:抗组胺剂H1添加到鼻内类固醇中对过敏性鼻炎治疗的影响研究

H1抗组胺剂(AH)和鼻内类固醇(INCS)组合治疗经常用于那些单独使用上述治疗效果不明显的过敏性鼻炎(AR)患者。最近,有研究人员进行了系统性的回顾来确定AH与INCS的组合(AH-INCS)对治疗AR的影响。研究人员利用Medline和Embase数据库进行了文献搜索,并包括了那些随机的、对照试验且研究AH-INCS与INCS单独治疗对治疗AR患者效果比较的文章。研究的初级结果为总鼻症状评分、

JCO:基线类固醇对非小细胞肺癌患者PD-1/PD-L1阻断治疗有效性的影响

PD-1或PD-L1抑制剂目前是肺癌患者的标准治疗方案。皮质类固醇激素的免疫抑制作用可能会降低PD-(L)1的有效性。皮质类固醇激素治疗免疫相关不良反应时看起来不会影响有效性,但是治疗开始时基线皮质类固醇激素的潜在影响尚不清楚。JCO近期发表了一篇文章,研究治疗开始时皮质类固醇激素的作用。

Crit Care Med:类固醇辅助治疗细菌性脑膜炎 应警惕迟发性脑损伤?

细菌性脑膜炎可导致严重的神经功能缺陷和死亡。脑梗死在肺炎球菌脑膜炎患者中特别常见,且在疾病的头几天内就会出现。 美国传染病协会和欧洲临床微生物学和传染病学会指南都建议使用抗菌药的同时辅助类固醇治疗。然而,在广泛实施辅助类固醇治疗后,曾有少数患者报道发生了迟发性脑损伤(DCI)事件。

Acta Otorrinolaringol Esp:在突发性感官听力损失中,鼓室内类固醇作为挽救治疗效果分析

突发性感官听力损失(ISSHL)被定义为突发性的听力损失,且不小于30dB,病因仍旧未知。最近,有研究人员分析了在起始的系统类固醇治疗失败后,利用鼓室内类固醇注射作为一种挽救治疗后,听力响应的结果。研究是一个观察性的研究,并在125个2006年到2014年诊断为ISSHL的患者中进行。其中,16名根据西格尔标准在治疗1周后完全恢复。剩下的109名患者被分成了2个小组:获取鼓室内类固醇挽救治疗(治疗

Hypertension:外周血类固醇水平可指示单侧原发性醛固酮增多症患者肾上腺切除术后的生化预后

单侧原发性醛固酮增多症(PA)是最常见的可通过手术治愈的高血压类型,治疗时需与双侧PA准确区分(手术 vs 药物)。肾上腺切除术几乎可在生化水平上治愈所有的确诊的单侧PA患者;其余部分或无生化治愈的患者包括术前误诊为单侧PA的持续性醛固酮增多症患者。为明确术后生化指标预后的决定因素,Lucie S. Meyer等人对肾上腺切除术后无或仅部分生化恢复的单侧PA患者的肾上腺组织病理和外周血类固醇水平进